We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
GlaxoSmithKline appears to be the frontrunner to buy Pfizer's consumer healthcare business after Reckitt Benckiser said that it ended its interest in the unit.
Reckitt Benckiser’s feelings about Pfizer’s consumer unit haven’t changed since the company said in 2015 that it’d be keen to buy it. But its resources have.